Miriam Manook1, Leonardo Koeser2, Zubir Ahmed1, Matthew Robb3, Rachel Johnson3, Olivia Shaw4, Nicos Kessaris1, Anthony Dorling5, Nizam Mamode6. 1. Department of Transplantation, Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital, London, UK. 2. King's Health Economics, Health Services and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience at King's College, London, UK. 3. NHS Blood & Transplant, Bristol, UK. 4. Clinical Transplantation Laboratory, Guy's & St Thomas' NHS Trust, Viapath, London, UK. 5. Department of Transplantation, Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital, London, UK; MRC Centre for Transplantation, King's College London, Guy's Hospital, London, UK. 6. Department of Transplantation, Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital, London, UK. Electronic address: nizam.mamode@gstt.nhs.uk.
Abstract
BACKGROUND: More than 40% of patients awaiting a kidney transplant in the UK are sensitised with human leucocyte antigen (HLA) antibodies. Median time to transplantation for such patients is double that of unsensitised patients at about 74 months. Removing antibody to perform an HLA-incompatible (HLAi) living donor transplantation is perceived to be high risk, although patient survival data are limited. We compared survival of patients opting for an HLAi kidney transplant with that of similarly sensitised patients awaiting a compatible organ. METHODS: From the UK adult kidney transplant waiting list, we selected crossmatch positive living donor HLAi kidney transplant recipients who received their transplant between Jan 1, 2007, and Dec 31, 2013, and were followed up to Dec 31, 2014 (end of study). These patients were matched in a 1:4 ratio with similarly sensitised patients cases listed for a deceased-donor transplant during that period. Data were censored both at the time of transplantation (listed only), and at the end of the study period (listed or transplant). We used Kaplan-Meier curves to compare patient survival between HLAi and the matched cohort. FINDINGS: Of 25 518 patient listings, 213 (1%) underwent HLAi transplantation during the study period. 852 matched controls were identified, of whom 41% (95% CI 32-50) remained without a transplant at 58 months after matching. We noted no difference in survival between patients who were in the HLAi group compared with the listed only group (log rank p=0·446), or listed or transplant group (log rank p=0·984). INTERPRETATION: Survival of sensitised patients undergoing HLAi in the UK is comparable with those on dialysis awaiting a compatible organ, many of whom are unlikely to be have a transplant. Choosing a direct HLAi transplant has no detrimental effect on survival, but offers no survival benefit, by contrast with similar patients studied in a North American multicentre cohort. FUNDING: UK National Health Service Blood & Transplant and Guy's & St Thomas' National Institute for Health Research Biomedical Research Centre.
BACKGROUND: More than 40% of patients awaiting a kidney transplant in the UK are sensitised with human leucocyte antigen (HLA) antibodies. Median time to transplantation for such patients is double that of unsensitised patients at about 74 months. Removing antibody to perform an HLA-incompatible (HLAi) living donor transplantation is perceived to be high risk, although patient survival data are limited. We compared survival of patients opting for an HLAi kidney transplant with that of similarly sensitised patients awaiting a compatible organ. METHODS: From the UK adult kidney transplant waiting list, we selected crossmatch positive living donor HLAi kidney transplant recipients who received their transplant between Jan 1, 2007, and Dec 31, 2013, and were followed up to Dec 31, 2014 (end of study). These patients were matched in a 1:4 ratio with similarly sensitised patients cases listed for a deceased-donor transplant during that period. Data were censored both at the time of transplantation (listed only), and at the end of the study period (listed or transplant). We used Kaplan-Meier curves to compare patient survival between HLAi and the matched cohort. FINDINGS: Of 25 518 patient listings, 213 (1%) underwent HLAi transplantation during the study period. 852 matched controls were identified, of whom 41% (95% CI 32-50) remained without a transplant at 58 months after matching. We noted no difference in survival between patients who were in the HLAi group compared with the listed only group (log rank p=0·446), or listed or transplant group (log rank p=0·984). INTERPRETATION: Survival of sensitised patients undergoing HLAi in the UK is comparable with those on dialysis awaiting a compatible organ, many of whom are unlikely to be have a transplant. Choosing a direct HLAi transplant has no detrimental effect on survival, but offers no survival benefit, by contrast with similar patients studied in a North American multicentre cohort. FUNDING: UK National Health Service Blood & Transplant and Guy's & St Thomas' National Institute for Health Research Biomedical Research Centre.
Authors: Jean Kwun; Marie Matignon; Miriam Manook; Soulef Guendouz; Vincent Audard; David Kheav; Elsa Poullot; Chantal Gautreau; Brian Ezekian; Diane Bodez; Thibault Damy; Laureline Faivre; Dehbia Menouch; Janghoon Yoon; Jaeberm Park; Karim Belhadj; Dongfeng Chen; Alyssa M Bilewski; John S Yi; Bradley Collins; Mark Stegall; Alton B Farris; Stuart Knechtle; Philippe Grimbert Journal: J Am Soc Nephrol Date: 2019-06-21 Impact factor: 10.121
Authors: Carrie A Schinstock; Andrew J Bentall; Byron H Smith; Lynn D Cornell; Matthew Everly; Manish J Gandhi; Mark D Stegall Journal: Am J Transplant Date: 2018-12-15 Impact factor: 8.086
Authors: Jean Kwun; Christopher Burghuber; Miriam Manook; Brian Ezekian; Jaeberm Park; Janghoon Yoon; John S Yi; Neal Iwakoshi; Adriana Gibby; Jung Joo Hong; Alton B Farris; Allan D Kirk; Stuart J Knechtle Journal: Blood Adv Date: 2017-10-26
Authors: Kyle R Jackson; Karina Covarrubias; Courtenay M Holscher; Xun Luo; Jennifer Chen; Allan B Massie; Niraj Desai; Daniel C Brennan; Dorry L Segev; Jacqueline Garonzik-Wang Journal: Am J Transplant Date: 2018-11-26 Impact factor: 8.086
Authors: Sebastiaan Heidt; Geert W Haasnoot; Marissa J H van der Linden-van Oevelen; Frans H J Claas Journal: Front Immunol Date: 2021-06-25 Impact factor: 7.561